Company intelligence / Profile preview
CellabMED
Seoul, South Koreacellabmed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CellabMED is developing CAR-T cell therapies for rare and intractable cancers, with their lead product CLM-103 having received IND approval in 2021. The company has secured multiple patent registrations across different countries for CLM-103.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- CAR-T cell therapyTherapeutic antibodiesCell and gene therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
HK InnoenSG MedicalKorea University's College of MedicineThe University of New South Wales (UNSW)
Beyond the preview
Go deeper on CellabMED.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellabMED.